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Abstract
The INK4a/ARF locus on the short arm of chromosome 9 is one of the most frequently altered loci in human cancer. It is
generally accepted that ARF is involved in oncogenic checkpoint pathways by sensitizing incipient cancer cells to undergo
growth arrest or apoptosis through both p53-dependent and independent pathways. While intensive studies have been
focused on ARF activation at the transcriptional level, only recently mechanisms governing ARF turnover have been
identified. Here, we show for the first time that p14ARF is a PKC target. Prediction analysis showed many potential
phosphorylation sites in PKC consensus sequences within ARF protein, and, among them, the threonine at position 8 was
the most conserved. Substitution of this threonine influences both ARF stability and localization. Furthermore,
a phosphomimetic ARF mutation reduces the ability to arrest cell growth although the ability to bind MDM2 and stabilize
p53 result unaffected. Thus we propose that phosphorylation of ARF in both immortalized and tumor cell lines could be
a mechanism to escape ARF surveillance following proliferative and oncogenic stress.
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Introduction
The ARF protein is encoded by the alternative reading frame of
the INK4a locus, one of the most frequent sites of genetic loss in
human cancers. Over the last years, a direct contribution of ARF
to tumor formation has been documented using genetic analysis of
tumors, molecular and cell biology methods and animal models
[1,2,3]. Both the human (p14ARF) and mouse (p19ARF) proteins
function as important sensors of hyper-proliferative stimuli acting
to restrict cell proliferation through both p53-dependent and
independent pathways [4,5]. Under normal conditions the p53
protein is kept at low levels by its rapid turn over, and exists in
a latent and inactive form. Activation of p53 in response to cellular
stresses is mediated, at least in part, by inhibition of MDM2
functions [6]. In normal conditions, primary cells contain low
levels of ARF. However, when stimulated to proliferate by
oncogenic proteins such as Myc, E2F, E1A, oncogenic Ras and
v-Abl [7,8,9,10], ARF levels increase. This phenomenon is
generally accompanied by a parallel disruption of the inhibitory
interaction between Mdm2 and p53, resulting in the accumulation
of transcriptionally active p53 that induces specific responses such
as cell-cycle arrest or apoptosis [11,12]. However, genetic analysis
of tumors and the evidence that ARF can induce cell-cycle arrest
in cells lacking Mdm2 and p53 support the notion that ARF might
act independently of MDM2 and p53 [2,5,13,14,15]. Further-
more, the discovery of a plethora of ARF interactors and the
observation that also viral, genotoxic, hypoxic and oxidative
stresses activate an ARF-dependent response, suggest that ARF
has a wider role to protect the cell [16]. Given its strong ability to
block growth and proliferation, cells must develop mechanisms
that promptly reduce either its expression or functions when its
activity is no longer required. While ARF activation, mostly
occurring through transcriptional activation, has been the focus of
intensive studies [17,18,19,20,21] only recently the mechanisms
regulating ARF protein turnover started to be elucidated. ARF
degradation can be regulated by the proteasome by both ubiquitin
independent [22] or lysine-independent N-terminal ubiquitylation
mechanisms [23]. Recently, a specific ARF ubiquitin ligase, ULF
has been identified [23,24]. Moreover, it has been observed that in
primary cells ARF turnover is very fast: these cells express very low
levels of protein, which could be promptly stabilized upon
proteasome inhibitor treatment. Conversely, ARF protein appears
to be very stable in cancer cells where proteasome-mediated ARF
degradation is severely impaired [24].
It has been reported that Protein Kinase C alpha (PKCa) is
involved in the stabilization of exogenously expressed ARF protein
levels [25]. Multiple PKC isoforms have been associated with
epidermal keratinocyte differentiation program and some of them
are activated by calcium [26]. We have previously shown that both
p14ARF transcript and protein levels increase upon calcium-
induced keratinocyte differentiation. Here we present data
showing that endogenous human ARF protein levels increase
following stimuli known to activate the PKC pathway in both
tumor and immortilized keratinocyte cell lines. A careful
examination of ARF protein sequence revealed three potential
PKC phosphorylation sites. Among them, Threonine at position 8
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lies within the most conserved region encompassing amino acids
2–14 and is required for the activity and nuclear localization of
ARF protein [26,27,28]. Our data indicate that mutation of this
residue, mimicking a phosphorylation status of the protein,
influences both ARF activity and cellular localization.
Results
p14ARF Protein Levels Increase following Calcium and
TPA Treatment
We had previously shown that, during calcium induced
differentiation of transformed human keratinocyte cells (HaCaT),
p14ARF increases both at protein and transcriptional levels [29].
To understand if the increase in ARF levels was due to
a transcription independent mechanism, HaCaT cells were
transfected with increasing amounts of a plasmid expressing
p14ARF and treated with 2mM calcium for 12h in presence of
serum. Western blot analysis of total protein extracts (Fig. 1a)
shows that ARF levels increase following stimulation. Quantifica-
tion of multiple esperiments shows a two fold increase of ARF
protein levels following calcium treatment (260,5). It has been
reported that PKCa, which can be activated by Ca2+, is involved
in TPA-mediated stabilization of p14ARF [25]. Thus we analysed
ARF protein levels in HaCaT cells treated with 10mM TPA
(Fig. 1b). The experiment shows that TPA induces a fast PKC
activation, followed by an increase of ARF protein levels after 10
minutes of treatment (2.560,09). Accordingly, a decrease of
almost 70% ARF levels (0,360,05) was obtained when cells were
grown in presence of 5mM bisindolylmaleimide, a known inhibitor
of PKC activation (Fig. 1c). Similar results were obtained using the
p53 deficient human lung cancer cell line H1299 expressing
endogenous ARF (data not shown). Altogether, these experiments
prompted us to further investigate on the potential role of PKC
and phosphorylation on p14ARF regulation.
p14ARF Interacts with and is Phosphorylated by PKC
in vitro
Analysis of ARF protein sequence with GPS 2.1 [30] software
revealed the presence of three potential PKC phosphorylation
sites. Among these, Threonine 8 and Serine 52 lie in the functional
active domain of the protein, while Serine 127 in the C-ter region
of the protein (Fig. 2a). Interestingly, threonine 8 is conserved
among all ARF orthologs. We thus performed an in vitro assay to
test ARF ability to be phosphorylated by PKC. Phosphorylation
assay was performed using a purified MBP::ARF protein and
a commercially available Protein Kinase C phosphorylation assay.
A reaction containing only the maltose binding protein was
performed in parallel, as negative control. Autoradiography
showed a clean phosphorylated MBP-ARF signal, indicating that
ARF is actually a PKC substrate (Fig. 2b, compare lane 2 with
lane 1). A fusion protein in which the three PKC consensus
sequences were simultaneously mutated was used as control. This
mutant was not phosphorylated in these experimental conditions,
thus confirming the specificity of the kinase assay (data not shown).
As many PKC substrates are dephosphorylated by PP1 [31], equal
aliquots of the reaction, after kinase incubation, were subjected or
not to a dephosphorylation assay using the Protein Phosphatase-1
(PP1) catalytic subunit. As shown in Fig2, panel B, the
phosphorylated ARF signal disappeared upon PP1 treatment
(compare lane 4 with lane 3). The ability of PKC to phosphorylate
a p14ARF mutant where the threonine 8 was replaced with an
alanine (MBP::p14ARF T8A) was also analysed. As shown in
Fig. 2c this mutant is still a PKC substrate even if at lesser extent
than the wt protein.
We next verified the physical association between ARF and
PKC by coimmunoprecipitation experiment in H1299 cells
expressing endogenous p14ARF (Fig. 2d). As a negative control
we used the human osteosarcoma U2OS cell line that is wild type
Figure 1. SDS-PAGE analysis of ARF protein levels. a) HaCaT cells were transfected with an empty plasmid (vector) and increasing amount of
p14ARF expression plasmid. Twenty-four hours after transfection cells were treated or not with 2mM Ca2+ as indicated. Cellular extracts were
immunoblotted and analysed with anti His antibody to detect exogenous ARF levels and anti actin as loading control. b) HaCaT cells were treated
with 10mM TPA for different time points. Protein extracts were subjected to WB with anti ARF (C-18) and an anti pPKC pan antibody that recognizes
all the PKC isoforms phosphorylated at a carboxy-terminal residue homologous to serine 660 of PKC b II (activated pPKC). Actin was used as loading
control. c) HaCaT cells were treated with 5mM Bisindolylmaleimide (Bim) for 12 hours (hrs) and analysed with anti ARF and anti actin antibodies.
doi:10.1371/journal.pone.0053631.g001
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for p53 but lacks expression of p16 and p14ARF proteins. Total
extracts were immunoprecipitated with anti ARF antibody and
complexes probed with anti ARF and anti phospho-PKC pan
antibody. Protein complexes were also assayed with an antibody
recognizing a well known ARF protein partner, the MDM2
oncoprotein, as positive control. As shown in Fig. 2 (panel d and e),
a complex between ARF and activated PKC is exclusively
detected in H1299 cells.
Mutation of Threonine 8 does not Affect ARF Folding
The conserved threonine at position 8 lies in a twelve amino
acid stretch (region 2–14, see Fig. 2a) strictly required for ARF
biological activity. To analyse the role of this residue in ARF
functions, we constructed ARF mutants where threonine 8 was
replaced either by an alanine residue, that cannot be phosphor-
ylated (T8A mutant), or by an aspartic acid (T8D mutant) that
mimics the phosphorylated status of the protein. To rule out the
Figure 2. ARF is a substrate of PKC and PP1 in vitro. a) Diagramatic scheme of p14ARF phosphorylation sites identified in silico. In light gray is
indicated the conserved 2–14 aminoacid stretch within the N-terminal exon 1b encoded domain (aminoacid 1–65), while in dark gray the exon 2
nuclear localization signal. PKC phosphorylation sites are shown in bold above the scheme, while other kinases target sites are denoted in gray below
the scheme b) In vitro phosphorylation assay. MBP (lane 1) and MBP::ARF (lane 2) were incubated with labelled cATP and catalytic PKC subunit.
Reactions were then subjected to SDS-page and WB followed by ON exposure (upper panel). The lower panel shows the same filter immunoblotted
with anti MBP antibodies. Detections of MBP::ARF is denoted by (*) on the autoradiograms and WBs. Purified phosphorylated MBP::ARF was divided in
two aliquots and incubated (lane 4) or not (lane 3) with catalytic PP1 and processed as described in a). c) In vitro phosphorylation assay of MBP::T8A
mutant. d) Co-immunoprecipitation of pPKC with ARF: H1299 lysates were incubated with anti-ARF antibody or with mouse IgG as negative control.
Samples were analyzed by immunoblotting with anti pPKC Ser660, anti ARF and anti MDM2 antibodies.
doi:10.1371/journal.pone.0053631.g002
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possibility that the inserted mutations could have resulted in an
uncorrectly folded protein, we tested the binding to MDM2,
interacting with the N-terminal ARF region [28], and to p32 that
binds ARF through the C-terminal domain [32]. U2OS cells were
transfected with expression plasmids encoding human MDM2 or
myc tagged p32, and/or X-press tagged wild type or mutant ARF
proteins (Fig. 3). Immunoprecipitated complexes were blotted and
probed with anti-MDM2, anti- myc and anti-ARF antibodies. The
experiments show that the substitution of threonine at position 8
does not affect ARF binding to MDM2 and p32 (Fig. 3a and b).
Mutation of Threonine 8 Affects ARF Protein Turn-over
Immunoblots of total cell lysates reproducibly showed lower
levels of T8A mutant compared to wt and T8D mutant suggesting
lower protein stability. To explore this possibility, half-life studies
of the wt and mutant proteins were performed using the protein
synthesis inhibitor cycloheximide (Fig. 4). Half-life analyses
showed that reduced expression of T8A mutant correlated with
decreased stability. Wild-type ARF showed a half-life of 6 hours, as
previously reported [33]. While T8D mutant stability is compa-
rable to that of the wt, the half-life of the T8A mutant is reduced to
2 hours, indicating that this residue could be involved in p14ARF
stability (Fig. 4a and 4b).
Mimicking Thr8 Phosphorylation Induces ARF
Accumulation in the Cytoplasm and Nucleus
It has been extensively shown that ARF amino acid stretch 2–14
is not only involved in MDM2 binding and ARF mediated cell
cycle arrest but also contribute to p14ARF nucleolar comparti-
mentalization [28,33]. Thus we analysed the effect of T8
mutations on ARF subcellular localization following transfections
in U2OS cells.
As expected, following transfection wt ARF protein presents
different localization patterns with cells showing three different
stainings: nucleolar (Fig. 5a panel i), nuclear (Fig. 5a panel ii) and
nucleo-cytoplasmic (Fig. 5a panel iii). Quantitation of this result
showed, for the wt protein, a clear nucleolar and nuclear
distribution pattern in the majority of transfected cells (90%),
and a nuclear-cytoplasmic distribution in the remaining 10% of
cells (Fig. 5b). The T to A substitution did not significantly
Figure 3. Mutation of Threonine 8 does not affect ARF folding. a) U2OS cells were transfected with plasmids encoding X-press tagged version
of either wild type or mutants ARF proteins alone or in combination with plasmid encoding human MDM2 protein. Cellular lysates were
immunoprecipitated with anti X-press antibody and samples analyzed by immunoblotting with anti MDM2 and ARF antibodies. b) cells were
trasfected with myc tagged p32 encoding plasmid and wt and mutants ARF as described in a). Cellular lysates were immunoprecipitated with anti
ARF and analysed by IB with anti myc and anti ARF antibodies.
doi:10.1371/journal.pone.0053631.g003
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compromise the number of cells showing a nuclear localization as
shown by quantitation in Fig. 5b. However, replacement of the
same residue with an aspartic acid dramatically reduced the
proportion of cells showing exclusively nucleolar ARF localization
and led to an increase in the percentage of cells with nuclear and
nuclear-cytoplasmic ARF staining (Fig. 5b). Experiments per-
formed with GFP fusion proteins gave similar results (data not
shown). These data suggest that a mutation mimicking T8
phosphorylation can induce accumulation of the protein both in
the cytoplasm and in the nucleus.
Cytoplasmic Localized ARF Protein is Phosphorylated
Endogenous ARF localization was then analysed in tumor
cells such as H1299 by western blot of cytoplasmic and nuclear
extracts. Efficient fractionation was checked with anti PARP-1
for nucleus and anti actin or RACK-1 antibodies for the
cytoplasm as these proteins are mainly enriched in these cellular
compartments (Fig. 6a and [34]). Using different ARF
antibodies, we consistently found an ARF immunoreactive band
both in nuclear and cytoplasmic extracts (Fig. 6a and data not
shown). Moreover, fractionation experiments, performed in the
HaCaT cell line, showed ARF expression almost exclusively in
the cytoplasm (Fig. 6a right panel), in agreement with our
previously published immunofluorescence data [29]. Western
blot analysis also shows that activated PKC is mainly localized
in the cytosol (Fig. 6a).
We next looked at the effect of TPA addition on the ARF
protein levels both in nuclear and cytoplasmic compartments. As
shown in Fig. 6b, following TPA treatment, only the cytoplasmic
pool of ARF increased. Consistently, pPKC appeared upregulated
in the cytoplasm. We thus decided to check the phosphorylation
status of cytoplasmic ARF by a lambda phosphatase treatment
(Fig. 7a). Equal amount of cytoplasmic extracts were incubated or
not with lambda phosphatase and subjected to SDS-page and
western blot with anti ARF antibody. The experiment clearly
shows an increase of the ARF band in the treated sample (compare
lane+with2) in both cell lines and using different ARF antisera
(data not shown).
We next assessed ARF phosphorylation status in H1299 cells
after TPA stimulation using a different approach. Cells were
treated with TPA and protein extracts subjected to immunopre-
cipitation with anti ARF antibody followed by immunoblot with
an antibody directed against phosphorylated threonine (pThr
antibody). The experiment shows a 15 KDa band in untreated
sample whose intensity increases following TPA stimulation
(Fig. 7b upper panel). Identity of this band was confirmed by
western blot with anti ARF antibodies (Fig. 7b lower panel).
Mimicking ARF Phosphorylation Inhibits ARF Biological
Activity
It has been repeatedly shown that ARF ectopic expression
inhibits cell proliferation at least in cells expressing wt p53
[33,35,36]. Wild type and mutant ARF ability to block pro-
liferation was tested by Colony formation efficiency assay (CFE
assay) in U2OS cells where p53 pathway is intact. Results showed
that, although less stable, T8A mutant was able to block cell
proliferation with the same efficiency as the wt (Fig. 8a). Ectopic
expression of the T8D mutant was instead less efficient (60%
residual colonies after G418 selection in T8D versus 30% of wt
and T8A, Fig. 8a). Similar results were obtained in the ARF null
NIH 3T3 mouse cells harbouring wt p53 (Fig. 8a). Interestingly,
western blot assays show that T8D ectopic expression is efficient in
stabilizing p53 (Fig. 8b).
Discussion
In this paper we report data showing that two known inducers
of PKC activation, Ca2+ and TPA, both induce an increase of
p14ARF protein level in immortalized and in tumor cell lines. The
PKC family consists of at least ten serine/threonine kinases
playing a central role in cell proliferation, differentiation, survival
Figure 4. Protein turn-over analysis. a) Half-life analysis of the wt and mutated p14ARF in human U2OS cells. Cells were transfected with p14ARF
wt, T8A and T8D plasmids and treated with cycloheximide (CHX) for the indicated times two days after transfection. ARF and actin levels were
analysed by WB of total extracts. b) The plot represents half-life analysis of wt and mutant ARFs. Band intensities were quantified by Image J analysis
and actin normalized before being plotted in graph. The amount of protein at different time points is expressed as percentage of total protein, i.e.
protein amount at t0. Each profile represents the mean of three independent transfections and WB experiments. Standard deviations are also shown.
doi:10.1371/journal.pone.0053631.g004
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and death [37]. While classical isoforms need both calcium and
the lipid molecules Diacylglycerol (DAG) or phorbol esters (TPA)
for activation, novel kinases are calcium independent and lipid
dependent, while atypical are both calcium and lipid independent.
Our results suggest that the PKC isoform(s) involved might belong
to the classical and/or novel subfamily. Accordingly, the in-
volvement of PKCa in TPA-mediated stabilization of p14ARF has
been reported [25]. PKCa, the major conventional Ca2+ re-
sponsive PKC in epidermis, is highly abundant in skin and is
believed to play a key role in calcium induced keratinocyte
differentiation [38,39]. Remarkably, defective differentiation in
skin cancer correlates with elevated PKCa activity. The positive
correlation between tumor promoting effects of various phorbol
esters with their ability to activate certain PKC isoforms, indicates
that PKC activation is a critical step in skin tumor promotion [40].
Accumulating data show that PKC is linked to promotion and
progression of several tumor types [41,42,43,44] and a number of
pharmacological PKC inhibitors are developed and currently used
in clinical trial. However, PKCs play either as oncogenes or tumor
suppressors in human cancer development [45] and, therefore, the
combined effects of the various PKC isoforms can result in diverse,
conflicting consequences depending on individual isozyme, cell-
type and subcellular localization.
Our findings that ARF is regulated through the activation of
PKC pathway led us to the hypothesis that ARF function might be
regulated by phosphorylation. ARF contains numerous potential
phosphorylation sites, and one study suggested that it could be
a target of death associated protein kinase (DAPK) [46].
Figure 5. ARF localization analysis. U2OS cells were transfected with p14ARF expression plasmids (wt or mutants) and visualized by IF with anti
histidine antibody. Nuclei were stained with DAPI. Images were taken with a Nikon fluorescent microscope. a) Visualization of the three different wt
ARF localization patterns are indicated with i, ii and iii. Scale bar: i, ii = 3mm; iii = 7mm. b) The histogram, representing the mean of three independent
experiments, reports the percentage of transfected cells showing each localization pattern. Standard deviations are also shown. Asterisks indicate
statistically significant differences between the sample and wt ARF (* = p,0.05; *** = p,0.001).
doi:10.1371/journal.pone.0053631.g005
Mimicking p14ARF Phosphorylation
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53631
Moreover, the potential involvement of phosphorylation in
controlling ARF activities has already been suggested by different
experimental approaches [47,48].
Our hypothesis is supported by several findings. First,
sequence prediction analysis shows that three PKC consensus
sequences are present within ARF protein sequence, and
in vitro kinase assay shows that the protein can be specifically
phosphorylated by PKC and dephosphorylated by PP1. In
agreement, a protein complex consisting of activated PKC and
ARF exists in cells, and we observed that immunoprecipitated
ARF can be recognized by a pThr antibody in the H1299 cell
line (Fig. 6b). Moreover, following TPA treatment, the amount
of phosphorylated ARF species increase (Fig. 6b lower panel).
Significantly, TPA-induced PKC activation results in the
stabilization of cytoplasmic ARF.
Furthermore, we have functionally characterized the role of the
conserved threonine 8 that lies within a PKC consensus sequence
in ARF protein. While the T8A mutation does not affect ARF
localization, the phospho-mimetic T8D mutation dramatically
reduces ARF ability to be exclusively localized in the nucleoli
inducing the protein to accumulate in the cytoplasm in a signif-
icative fraction of cells. The observation that l phosphatase
treatment results in a clear thickening of the ARF electrophoretic
band, suggests that the cytoplasmic protein is indeed phosphor-
Figure 6. Sub-cellular fractionaction. H1299 cells, endogenously expressing p14ARF, were subjected to subcellular fractionation. a) Left panel:
cytoplasmic (Cy) and nuclear extracts (Nu) from equal number of cells were subjected to SDS-page and immunoblot with anti PARP-1 (nuclear), actin
and RACK-1 antibodies (cytoplasm), anti pPKC and anti ARF antibodies. Right panel: HaCaT cells were subjected to subcellular fractionation and
analysed as previously described. Histone H1 is a control of nuclear extracts. Cytoplasmic ARF species are indicated by an asterisk (*). b) H1299 cells
were treated with TPA and subsequently subjected to subcellular fractionation. Equal amount of cytoplasmic (left panel) or nuclear (right panel)
extracts were immunoblotted with anti ARF, pPKC, and actin and histone H1 as loading control for cytoplasm and nucleus respectively, as described.
WB shown are representative of at least three independent experiments. Normalized ARF band intensities, shown below each corresponding band,
are expressed as fold enrichment respect to untreated samples arbitrarily set to 1 (see material and methods for details).
doi:10.1371/journal.pone.0053631.g006
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ylated. On the basis of these results we speculate that multiple
phosphorylated ARF species are present in the cytoplasm, and,
after phosphatase treatment, converge to the 15Kd band,
increasing its intensity. Accordingly, the MBPT8A ARF mutant
is still a PKC substrate in vitro (Fig. 2c), suggesting that multiple
sites could be phosphorylated within the endogenous protein, as
indicated by in silico analysis. Finally, while the T8A mutant
retains the ability to inhibit proliferation as the wt protein, the
phosphomimetic mutant T8D is severely impaired in the control
of cell proliferation. Interestingly, both MDM2 binding and p53
stabilization appear to be unaffected by the T8D mutation. These
results are in agreement with the notion that ARF dependent p53
activation takes place in the nucleus [47,49], and suggest that the
partial loss of function observed with the T8D mutant could be
ascribed to p53 independent ARF activities specifically impaired
by the T8D mutation. Our data also suggest that, at least in a p53
plus cell environment, the unphosphorylated protein is active in
blocking cell proliferation.
Analysis of protein turnover shows that the T to A substitution
strongly reduces protein half-life from six to two hours. Despite its
short half-life, T8A retains both nucleolar localization and control
of cell progression abilities. Given that it is expressed at very low
levels respect to the wt protein, the experiments indicate that few
active ARF molecules can guarantee an efficient control of cell
proliferation [50,51].
Altogether our data suggest that, following activation of PKC,
ARF protein is phosphorylated and accumulates in the cytoplasm
where it is unable to efficiently control cell proliferation. Further
experiments are needed to precisely identify the molecular
pathway, the potential involvement of additional kinase/s and
the ARF residues directly involved in this mechanism.
In conclusion we suggest that in a tumor environment, where
PKC is activated, ARF levels increase but its growth inhibitory
Figure 7. ARF phosphorylation assays. a) l phosphatase assay: equal amount of HaCaT and H1299 cytoplasmic extracts were incubated (lane 2
and 4) or not (lane 1 and 3) with l protein phosphatase (l PPase), analysed by high resolving SDS-PAGE and blotted with anti ARF antibody. Actin is
a loading control, while anti pAKT immunoblot is a reaction control. ARF band intensities, quantified as previously described, are also given. b)
Immunoprecipitation: H1299 cells treated or not with TPA were immunoprecipitated with anti ARF antibody, subjected to SDS-page and blotted with
anti pThr antibody (upper panel). The filter was stripped and incubated with anti ARF antibody (lower panel).
doi:10.1371/journal.pone.0053631.g007
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function is impaired. Interestingly, despite its role in growth
suppression, ARF is overexpressed in a significant fraction of
human tumors [52]. These observations, together with our
findings underscore the need for a careful re-evaluation of the
status and role of p14ARF in human cancer.
Our observations uncover a novel mechanism through which
cancer cells might escape ARF surveillance during cancer
progression. A deeper understanding of the PKC dependent
ARF functions may provide previously unknown and critical
therapeutic targets for cancer treatment.
Materials and Methods
Cell Culture, Cloning, Protein Expression and Reagents
The human epithelial cell line HaCaT was obtained from Dr.
Antonio Costanzo, Department of Dermatology, University of
Rome Tor Vergata, 00133 Rome, Italy. All other cell lines
(U2OS and H1299) were purchased from the American Type
Culture Collection (ATTC). Cells were grown in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine
serum (Euroclone, Life Science) at 37uC in a humidified
atmosphere of 5% (v/v) CO2 in air. Cells were transfected
using LipofectAMINE 2000 reagent (Invitrogen). For CFE
Figure 8. Growth suppression by wt and mutant ARF proteins. a) Graph indicating ARF and mutants ability to inhibit cell proliferation. U2OS
and NIH cells were transfected with the indicated amounts of ARF and mutant expression vectors. After two weeks selection to isolate transfected
colonies, cells were fixed and stained with crystal violet. The plot represents the percentage of colonies obtained with the indicated plasmids relative
to that detected with the empty vector. Values represent the mean of four independent experiments. Standard deviation for each value is also given.
Asterisks (*) indicate statistically significant differences (p,0.001) for the mutant samples compared to wt ARF. b) Western blot showing p53
stabilization following ARF (wt and mutant) transfection in U20S cells.
doi:10.1371/journal.pone.0053631.g008
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analysis U2OS were trasfected with calcium phosphate pre-
cipitation as previously described [53].
The T8 amino acid changes were inserted into human p14ARF
by site-directed mutagenesis using a wild-type p14ARF cDNA
template. Standard polymerase chain (PCR) reaction conditions
were used with each set of primers containing the desired
mutations, and all products were verified by sequencing before
subcloning into pMal, pcDNA3.1 and pEGFP vectors.
Antibodies used in this study: anti PARP-1 and anti-phospho-
PKC (pan) antibody (Beta IISer660) (from Cell Signaling
Technologies 9542, Boston, MA, USA); anti RACK-1 B3, anti
ARF C-18, anti actin I-19, Anti HistoneH1 N-16, anti p53 DO-1,
anti MDM2 SMP-14, (from Santa Cruz); anti ARF 4C6/4
(Abcam); anti ARF Ab2 14PO2 (Neomarkers); 6XHIS mono-
clonal antibody (Clontech); anti myc antibody 06549 (Upstate);
anti X-press monoclonal antibody (Invitrogen); anti pThreonine
Q7 (Qiagen). Western blot (WB) analysis was performed as
previously described [29]. The molecular weight marker used for
SDS page is the PageRulerTM Prestained Protein Ladder
(Fermentas and Pierce). Extracts were blotted onto PVDF
Immobilon-P transfer membrane (Millipore cat. NO.
IPVH00010). Proteins were visualized with an enhanced chemi-
luminescence detection system (Amersham ECLplus TM) and
images were taken with ChemiDoc XRS System (Bio-Rad
Laboratories) and analysed with the QuantityONE software
except when differently indicated.
Reagents used in this study: TPA was purchased from
Applichem, Cycloheximide and Bisindolylmaleimide from Cal-
biochem. TPA and cycloheximide were dissolved in DMSO and
used at 10mM and 80 mg per ml respectively. Bisindolylmaleimide
(Bim) was used at 5mM final concentration. ARF band intensities
following various treatments (Fig. 1–6–7) were quantified,
normalized to actin (or to histone H1 in case of nuclear extracts
in fig. 6) and reported as fold increase or decrease compared to
untreated sample. Each value represents the mean of three
independent experiments 6 standard deviations.
Protein Turnover Analysis
For half-life studies, transfected U20S were replated onto 6-well
dishes, allowed to adhere overnight, and treated with cyclohex-
imide or left untreated (0 hour control) for various time points.
Cells were harvested and p14ARF protein levels examined by WB
analyses of whole cell lysates with anti ARF antibody (C-18, Santa
Cruz) and actin as loading control. Band intensities at the different
time points were quantified by Image J Software, normalized to
actin and reported in graph as percentage of total protein (protein
a t0). Each profile represents the mean of three independent
experiments. Standard deviations are also shown.
Subcellular Localization Assay
U2OS cells (5.06104) were plated in 35 mm dish on micro
cover glasses (BDH) and transfected with 0.5mg of plasmid
expressing wt or mutant ARF. At 24 hrs after transfection with
the indicated vectors, cells were washed with cold phosphate-
buffered saline (PBS) and fixed with 4% paraformaldehyde
(Sigma-Aldrich, Germany) for 15 min at RT. Cells were
permeabilized with ice cold 0.5% Triton X-100 for 5 min and
then washed with PBS. Subcellular localization were determined
by using the monoclonal antibody against 6XHis, 1h a RT,
followed by incubation with a Cy3-conjugated anti-mouse
antibody (ImmunoResearch Laboratory) at 37uC for 30 min.
After PBS/0.05% Tween washing, the cells were incubated with
DAPI (Sigma-Aldrich, Germany) for 3 min and washed with PBS/
0.05% Tween. Coverslip were mounted with Vectashield
(VectorLab) and examined under a fluorescence microscope
(Nikon). For each transfection point, subcellular localizations were
analysed in 100–150 cells and results plotted in graph. Histograms
(% of transfected cell 6 S.D.) represent the mean of at least three
independent transfection experiments. Statistical analysis of
variance (Anova plus Bonferroni post test) was performed using
GraphPad Prism 5.0 software.
Subcellular fractionation of H1299 and HaCaT cells was
carried out as by Colucci-D’Amato et al., 2000 [54] with minor
modifications. In order to analyse ARF protein distribution in the
nuclear and cytoplasmic compartments, same number of cells and
nuclei were processed as described. Cells were harvested, washed
in ice cold PBS, resuspended in hypotonic buffer (Hepes 10mM,
KCl 60mM, DTT 1mM plus protease inhibitors) and incubated
on ice for 20 minutes. Following addition of NP-40 (0.2% final
concentration) cells were further incubated 1 minute on ice and
spun at 600g for 5 minutes. Supernatants were subsequently
centrifuged at 13000 rpm for 15 min to pellet unbroken nuclei
and organelles to obtain clear cytoplasmic lysates. Nuclei were
briefly washed in hypotonic buffer to eliminate traces of detergent,
purified on sucrose cushion, counted and lysed in RIPA buffer. To
verify the purity of the subcellular fractionation, anti-PARP1, anti
Histone H1, anti-rack1 and anti actin antibodies have been used in
WB.
Proliferation Assay
For the CFE assay (colony formation efficiency assay) U2OS
(16105 cells per well) cells were seeded into 6-well multiplates,
transfected with 2 mg of total plasmid DNA using the standard
calcium phosphate method and processed as previously described
[53]. Graphs (% of remaining colonies6 S.D.) represent the mean
of at least four experiments. Statistical analysis of variance was
performed as previously described.
p53 Stabilization Assays
Stabilization of p53 was performed in U2OS transfected with
wt, T8A and T8D mutant plasmid constructs. Protein levels were
analysed 24h after transfection with anti ARF (C-18), anti p53
(DO-1) and anti actin antibody as loading control.
Phosphorylation Assays
The MBP::ARF fusion proteins (both wt and mutants) were
obtained as previously described [53] and subjected to an in vitro
phosphorylation assay using a commercially available kit following
manufacturer instructions (Stratagene). PP1 dephosphorylation
assay was performed with the catalytic PP1 subunit (Promega)
following manufacturer instructions.
Lambda-phosphatase (l-PPase; New England Biolabs) treat-
ment was performed as previously described [55]. Immunopre-
cipitation following TPA treatment: 4 mg of total cellular extracts
of H1299 cells treated or not with TPA (10mM for 2 min) were
lysed in IP buffer (Tris-HCl pH7 10mM, NaCl 150 mM, SDS
0.1%, Triton-X100 1%, EDTA 1mM, EGTA 0,5mM) plus
protein phosphatase inhibitors. Cleared lysates were incubated
with 3mg of anti ARF (Ab2 14PO2, Neomarkers) ON. After
washing immunocomplexes were subjected to SDS-page on a 13%
gel followed by incubation with anti pThreonine (1:100 dilution in
3%BSA) followed by chemioluminesce (Pierce). The filter was then
stripped and incubated with anti ARF antibody (C-18) in order to
visualize total immunoprecipitated ARF protein.
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Co-Immunoprecipitation
ARF/pPKC co-immunoprecipitation assay were performed
with 2 mg of total cellular extracts. Cells were harvested, lysed
with co-ip buffer (Tris-HCl pH7 10mM, NaCl 150 mM, NP40
0.5%, glycerol 10%, EDTA 0.5mM) and incubated ON with anti
ARF antibody (C-18 Santa Cruz). After washing immunocom-
plexes were subjected to WB and analysis with anti pPKC pan
antibody (Beta IISer660, Cell Signalling), anti ARF (Ab2 14PO2,
Neomarkers) antibody and anti MDM2 antibody.
ARF (wild type and mutants)/MDM2 or myc tagged p32 co-
immunoprecipitation assays were performed with 1 mg of total
cellular extracts. Twenty-four hours following transfection cells
were harvested and processed as described. Ip were carried out
with anti X-press antibody and immunoprecipitated samples
analysed by WB with anti MDM2, anti myc and anti ARF
antibodies.
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